BlossomHill CMO holds options on 152,373 shares

Q: What does the Form 3 filing disclose about BLSM Chief Medical Officer Geoffrey Oxnard?

The Form 3 shows Geoffrey Raymond Oxnard’s initial ownership in BlossomHill Therapeutics, including stock options and common shares he holds directly as an officer of the company.

Q: How many stock options does Geoffrey Oxnard hold in BLSM and at what exercise prices?

Geoffrey Oxnard holds options over 152,373 BLSM shares at $5.63 and 34,031 shares at $6.28. Both option grants relate to underlying common stock and are held directly.

Q: When do Geoffrey Oxnard’s BLSM stock options expire?

Geoffrey Oxnard’s BLSM options on 152,373 shares expire on January 2, 2035, and his options on 34,031 shares expire on August 21, 2035. These expiration dates define how long he can exercise the options.

Q: How many BlossomHill Therapeutics (BLSM) common shares does Geoffrey Oxnard directly own?

Geoffrey Oxnard directly owns 17,785 shares of BLSM common stock. This direct share ownership is separate from his stock options and represents his current non-derivative equity stake.

BlossomHill Therapeutics, Inc. (BLSM) reported initial equity holdings for Chief Medical Officer Geoffrey Raymond Oxnard.

Accepted by SEC EDGAR 08/06/2026 - 08:37 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

BlossomHill Therapeutics, Inc. (BLSM) reported initial equity holdings for Chief Medical Officer Geoffrey Raymond Oxnard. He holds options immediately exercisable for 152,373 shares of common stock at an exercise price of $5.63 expiring January 2, 2035 and options for 34,031 shares at $6.28 expiring August 21, 2035, all held directly. He also directly holds 17,785 common shares. This filing reports existing positions and does not reflect any new purchases or sales.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Oxnard Geoffrey Raymond

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Holding	Employee Stock Option (Right to Buy) ^F1	--	--	--
Holding	Employee Stock Option (Right to Buy) ^F1	--	--	--
Holding	Common Stock	--	--	--

Holdings: Employee Stock Option (Right to Buy) — 186,404 contracts (Direct); Common Stock — 17,785 shares (Direct)

Footnotes (1)

F1. Immediately Exercisable.

Key Figures

Options underlying shares at $5.63: 152,373 shares Options underlying shares at $6.28: 34,031 shares Common stock directly held: 17,785 shares +2 more

5 metrics

Options underlying shares at $5.63 152,373 shares Employee Stock Option, exercise price $5.6300, expiration January 2, 2035

Options underlying shares at $6.28 34,031 shares Employee Stock Option, exercise price $6.2800, expiration August 21, 2035

Common stock directly held 17,785 shares Non-derivative common stock position held directly after reported holdings

Exercise price of first option grant $5.63 per share Employee Stock Option, underlying 152,373 shares of common stock

Exercise price of second option grant $6.28 per share Employee Stock Option, underlying 34,031 shares of common stock

Key Terms

Employee Stock Option (Right to Buy), exercise price, underlying security, Immediately Exercisable

4 terms

Employee Stock Option (Right to Buy) financial

"security_title is listed as Employee Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price is shown as 5.6300 and 6.2800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying_security_title is shown as Common Stock"

Immediately Exercisable financial

"footnote F1 states Immediately Exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing disclose about BLSM Chief Medical Officer Geoffrey Oxnard?

The Form 3 shows Geoffrey Raymond Oxnard’s initial ownership in BlossomHill Therapeutics, including stock options and common shares he holds directly as an officer of the company.

How many stock options does Geoffrey Oxnard hold in BLSM and at what exercise prices?

Geoffrey Oxnard holds options over 152,373 BLSM shares at $5.63 and 34,031 shares at $6.28. Both option grants relate to underlying common stock and are held directly.

When do Geoffrey Oxnard’s BLSM stock options expire?

Geoffrey Oxnard’s BLSM options on 152,373 shares expire on January 2, 2035, and his options on 34,031 shares expire on August 21, 2035. These expiration dates define how long he can exercise the options.

How many BlossomHill Therapeutics (BLSM) common shares does Geoffrey Oxnard directly own?

Geoffrey Oxnard directly owns 17,785 shares of BLSM common stock. This direct share ownership is separate from his stock options and represents his current non-derivative equity stake.

Are Geoffrey Oxnard’s BLSM stock options currently exercisable?

Yes. A footnote specifies that the reported employee stock options are “Immediately Exercisable”. This means Oxnard can choose to exercise these options for BLSM common shares at their stated exercise prices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Oxnard Geoffrey Raymond

(Last)

(First)

(Middle)

C/O BLOSSOMHILL THERAPEUTICS, INC.

10255 SCIENCE CENTER DRIVE, SUITE 200

(Street)

SAN DIEGO

CALIFORNIA

92121-1180

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/06/2026

3. Issuer Name and Ticker or Trading Symbol
BlossomHill Therapeutics, Inc. [ BLSM ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	17,785	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (Right to Buy)	⁽¹⁾	01/02/2035	Common Stock	152,373	$5.63	D
Employee Stock Option (Right to Buy)	⁽¹⁾	08/21/2035	Common Stock	34,031	$6.28	D

Explanation of Responses:

1. Immediately Exercisable.

	/s/ Vincent Liptak, Attorney-in-Fact	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR